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Abstract
Background: To determine the clinical effectiveness of statins on cardiovascular mortality in practice, observational
studies are needed. Control for confounding is essential in any observational study. Falsification end-points may be
useful to determine if bias is present after adjustment has taken place.
Methods: We followed starters on statin therapy in the Netherlands aged 46 to 100 years over the period 1996 to
2012, from initiation of statin therapy until cardiovascular mortality or censoring. Within this group (n = 49,688, up
to 16 years of follow-up), we estimated the effect of adherence to statin therapy (0 = completely non-adherent,
1 = fully adherent) on ischemic heart diseases and cerebrovascular disease (ICD10-codes I20-I25 and I60-I69) as
well as respiratory and endocrine disease mortality (ICD10-codes J00-J99 and E00-E90) as falsification end
points, controlling for demographic factors, socio-economic factors, birth cohort, adherence to other cardiovascular
medications, and diabetes using time-varying Cox regression models.
Results: Falsification end-points indicated that a simpler model was less biased than a model with more controls.
Adherence to statins appeared to be protective against cardiovascular mortality (HR: 0.70, 95 % CI 0.61 to 0.81).
Conclusions: Falsification end-points helped detect overadjustment bias or bias due to competing risks, and thereby
proved to be a useful technique in such a complex setting.
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Background
Statins are cholesterol lowering drugs whose efficacy in
reducing cardiovascular mortality was demonstrated in
various clinical trials (e.g. [1, 2]). However, evidence
from trials does not necessarily give a good indication of
drug effects for end users; trial participants differ from
patients in clinical practice in terms of demography,
concomitant drug use and co-morbidity [3, 4]. To deter-
mine the clinical effectiveness of drugs, observational
studies are needed. However, in an observational setting,
confounding factors may distort effect estimates. In
observational studies of the effect of statin therapy on
cardiovascular outcomes, healthy user bias and con-
founding by indication are most likely present, though
many other sources of bias may also exist.
Patients who are prescribed statins have a higher base-
line risk of cardiovascular mortality than patients who
have not been prescribed statins. Therefore, comparisons
of statin-users cannot easily be compared with non-
users, risking confounding by indication. By comparing
statin-users among each other, for example by looking at
adherence to prescribed regimen, confounding by indi-
cation is reduced. However, such a comparison risks
healthy adherer bias because higher adherence may cor-
relate with a healthier lifestyle and higher adherence to
other cardiovascular drugs. Ideally, such factors are con-
trolled. In the absence of direct measures of lifestyle,
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behavioral proxies such as neighborhood characteristics
or birth cohort may provide a solution [5–7].
The utility of proxies to reduce confounding is setting
dependent, and may be unknown. Therefore, other
checks are also required. In particular, falsification end-
points (also known as negative controls) may provide a
useful indicator of bias [8]. Falsification end-points are
outcomes that are not causally affected by the primary
exposure. If the primary exposure appears effective in re-
ducing (or increasing) the risk of the primary outcome,
this is an indication of bias, though the reverse is not ne-
cessarily true [9].
The aim of this study is to investigate the role of bias
in an assessment of the effect of adherence to statin
therapy on cardiovascular & cerebrovascular mortality
among statin users in the Netherlands over the period
1994 to 2010.
Methods
Study population of starters of statin therapy
The study population consisted of outpatients that initi-
ated statin therapy between ages 46 and 100 in the study
period 1996 to 2012, belonging to birth cohorts 1911 to
1960 in the Netherlands. These age and time ranges
constitute nearly all statin users in the Netherlands in
the past decades; prevalence of statin use remains ex-
tremely below age 45 years and statins were introduced
in the Netherlands around 1994 [5]. Approval from an
institutional review board was not required to perform
this study.
Data sources
We linked outpatient pharmacy data from the University
Groningen drug dispensing database (IADB.nl) to
patient-level and neighborhood-level data from Statistics
Netherlands. The IADB contains dispensing information
from 55 community pharmacies in the Netherlands, cov-
ering on average 500,000 persons annually (www.IADB.nl)
[10]. The database’s pharmacy information includes,
among others, name of the drug, anatomic–therapeutic–
chemical (ATC) classification and date of dispensing. With
the exception of over-the-counter drugs and in-hospital
dispensings, all dispensings are included regardless of pre-
scriber, insurance, or reimbursement status. Medication
records of patients are virtually complete because of high
patient pharmacy commitment in the Netherlands [10].
The IADB ensures anonymity of patients by using an-
onymous identifiers. The IADB has been used in previous
studies on statin use [5, 11]. IADB data was linked to
data on socio-economic covariates from Statistics
Netherlands using deterministic linkage based on date
of birth, sex and location of residence at various points
in time. For this study, we selected patients who were
part of the catchment area of the IADB pharmacies,
but were not living in areas from which patients were
more likely to visit other (non-IADB) pharmacies. Pa-
tients could be followed up to 16 years. Patients that
moved out of the IADB area were censored, as they
are then more likely to receive drugs from other
pharmacies.
Data availability
Data from the IADB and Statistics Netherlands were
not openly accessible. They were accessed after re-
ceiving permission from IADB (IADB.nl) and Statis-
tics Netherlands, respectively. Linkage of the two
datasets was performed by Statistics Netherlands, with
permission and cooperation from the IADB.
Primary exposure
The primary exposure of interest is time-varying adher-
ence to statin therapy (ATC-code C10AA and C10B)
[12]. In short, the time-varying adherence method calcu-
lates adherence using the proportion of days covered
between dispensing k and dispensing k + 2, and then
averages the adherence to 30-days intervals [12]. We in-
cluded all starters of statin therapy in the database. Indi-
viduals were considered to be a starter of statin therapy
if they did not receive statins in a period of 12 months
prior to a statin dispensing. The first date of dispensing
was considered the index date.
Primary outcome measure
The outcome of this study is time from initiation of sta-
tin therapy to cardiovascular mortality in 30-day units.
Cardiovascular mortality was defined as mortality due
to ischemic heart diseases (ICD10-codes I20-I25) or
mortality due to cerebrovascular disease (ICD10-codes
I60-I69) [13].
Falsification outcome measure
Statins should primarily reduce cardiovascular mortality
through a reduction in blood lipid concentration. There-
fore, it should not have a strong protective effect against
mortality due to diseases of the respiratory system
(ICD10-codes J0-J99) and endocrine, nutritional and
metabolic diseases (ICD-10 code E0-99). The endocrine
disorders include diseases of the thyroid, pituitary and
adrenal gland, pancreas and gonads. We applied our
small and large models also to these causes of deaths,
which can therefore be seen as negative controls, also
known as a falsification endpoint [14, 15].
Patient-level covariates
Patient-level variables that were included in the mod-
elling process, because they represented potential con-
founders, were demographic variables, drug utilization
variables and calendar year of observation. The
Bijlsma et al. BMC Public Health  (2016) 16:303 Page 2 of 8
demographic variables were: sex (male or female), and age
in 5-year categories (going from category 46–50 to cat-
egory 96–100). Drug utilization variables were time-
varying variables measuring adherence and exposure
levels of the following drugs: drugs used in diabetes (ATC
code A10), anti-inflammatory and anti-rheumatic drugs
(ATC M01), anti-thrombotic drugs (ATC B01), drugs for
obstructive airway diseases (ATC R03), cardiac therapeu-
tics (ATC C01), anti-hypertensives (ATC C02), diuretics
(ATC C03; this category also includes important anti-
hypertensives), beta blocking agents (ATC C07), calcium
channel blockers (ATC C08) and agents acting on the
renin-angiotensin system (ATC C09). Drug exposure level
was measured in daily defined dosage (DDD).
Aggregate-level covariates
In the modelling process, we also included a variable
on neighborhood socio-economic score (SES), and
birth cohort in 5-year categories (going from category
1911–1915 until category 1956–1960). Both of these
variables may be associated with health behavioral in-
formation [5–7, 16]. Adjustment for these variables
may therefore reduce the influence of healthy adherer
bias. Birth cohort has been shown to be associated
both with drug utilization and with cardiovascular
outcomes [5, 17–20]. Since the potential of birth co-
hort to confound or to modify effects is less known,
we also specifically tested whether birth cohort con-
tained confounding information by fitting models with
and without birth cohort, and tested whether it was
an effect modifier.
Statistical analysis
To measure the effect of statin adherence on the hazard
of cardiovascular mortality while controlling for other
variables, we applied Cox models with time from initi-
ation of statin therapy to cardiovascular mortality as the
outcome. Patients who experienced mortality due to
other causes of death were censored at their transition
time. We lagged drug utilization variables by one year
relative to the outcome as we did not expect changes in
drug regimen to have a short-term effect on cardiovas-
cular mortality.
Firstly, we built a model with statin adherence and sta-
tin drug exposure level, age, and calendar year. We used
partial likelihood ratio tests to determine if any of these
variables should be entered as categorical variables or as
continuous variables (and potentially continuous with a
squared term). We refer to this model as the ‘small’
model, due to many potential confounders being ex-
cluded from it. Secondly, we built the ‘large’ model using
the following variable inclusion criteria: variables were
added if they significantly added to the model according
to a partial likelihood ratio test (first step), or if they did
not significantly add to the model but their addition re-
sulted in a more than 5 % change in the statin effect es-
timate (second step, as non-significant variables may
also be confounders). Once the model was built, birth
cohort was entered as a categorical variable. In order to
avoid an identification problem occurring due to the lin-
ear dependency between age, period and cohort [21], we
constrained the effect of the 1916–1920 birth cohort to
be equal to that of the 1951–1955 cohort. Due to these
constraints, birth cohort only measured non-linear
effects. Statistical interaction terms between statin ad-
herence and birth cohort were added to the model and a
partial likelihood ratio test was used to determine the
presence of effect modification.
Cox models are non-collapsible, i.e. conditional effect
estimates of the model may not equal population-
averaged effect estimates [22]. Therefore, to determine
the public health effect of statin adherence, we also ap-
plied the parametric G-formula [23, 24]. This meant that
we fitted regression models to our empirical data to esti-
mate the complete joint distribution of cardiovascular
mortality, censoring, and measured confounders. This
estimated joint distribution was then used to simulate
the risk of cardiovascular mortality if all patients were
100 % adherent, and to compare it with the simulated
risk if all patients were 0 % adherent. This produced a
population-averaged hazard ratio of cardiovascular mor-
tality. Potential confounding by birth cohort was deter-
mined by comparing a hazard ratio produced in this
manner while including birth cohort in the estimation of
the joint distribution, with the hazard ratio produced
without including birth cohort in the estimation.
Subset analyses
We determined the influence of prescribing guidelines
on the amount of measured confounding by applying
the small Cox model and then the large Cox model for
patients in the period 1996–2002, 2003–2006, and




The sample consisted of 49,688 patients, of which 52 %
was male. The majority of patients at the start of statin
therapy, and thereby at the start of follow up, were in
age category 56–60 years. Of the patients that were cen-
sored, more than 90 % were censored in the final calen-
dar year of study. The majority of patients also received
other cardiovascular drugs next to statins (Table 1).
In our data, 64.8 % of patients started on Simvastatin,
19.1 % on Atorvastatin and 9.3 % on Pravastatin, with
the remainder being other types of statins. However,
some patients also switched drugs during follow-up.
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During follow-up, 32.7 % of patients switched to another
statin or to a fibrate. Switchers switched on average 2.8
times. By far the most common switch was from Simva-
statin to Atorvastatin (Table 2).
Within our sample, we found that the average DDD of
statin therapy gradually increased over time from about
1.03 DDD at the start to about 1.3 DDD at the end of
follow-up (ca. 5000 days later).
Statin adherence
Average adherence to statin therapy decreased strongly
in the first 1000 days of follow up, until approximately
74 % adherence. Adherence then remained approxi-
mately constant over time (Fig. 1). For the majority of
observations, individual patients were either highly ad-
herent (adherence ≥ 0.95) or highly non-adherent (adher-
ence ≤ 0.05). The percentage fully adherent appeared to
remain stable, while the percentage non-adherent
increased over time.
Mortality
During the study period from 1996 to 2010, of the
49,688 patients in the sample, 1033 died due to ischemic
heart disease and 532 due to cerebrovascular disease,
which together form the category ‘cardiovascular mor-
tality’. Non-cardiovascular causes were responsible for
6594 deaths among these patients. Among these non-
cardiovascular causes, 1179 died from the falsification
end-point.
Small Cox model
In a model including statin adherence, statin exposure
level, age and age squared as continuous variables, and
period as categorical variable, the conditional estimate
was that being fully adherent reduced the hazard of car-
diovascular mortality by about 30 % (HR: 0.70, 95 % CI:
0.61 to 0.81) compared to being fully non-adherent
(Table 3). Birth cohort did not add significantly to this
model (p = 0.51), and its addition did not change the
parameter estimate of statin adherence. The interaction
term between statin adherence and birth cohort also did
not add significantly to the model (p = 0.81).
Large Cox model
The final model included the following variables as con-
tinuous variables: statin adherence and exposure level,
age and age squared, diuretic adherence and exposure
level, and obstructive airway drug adherence and expos-
ure level. A number of other variables were added as
categorical variables: calendar year, sex, anti-thrombotic
agent adherence and exposure level, anti-inflammatory
& anti-rheumatic drug adherence and exposure level,
cardiac therapy adherence and exposure level, beta-
blocking agent adherence and exposure level, and cal-
cium channel blocker adherence and exposure level.
Birth cohort did not add significantly to this model
(p = 0.61), and adding birth cohort did not have a strong
effect on the effect estimates of statin adherence. Socio-
economic status also did not add significantly to the
model (p = 0.83). The final model did not include the dia-
betes treatment variable because the effect estimate of st-
atin adherence did not change more than 5 % after
adjustment for diabetes treatment. The conditional esti-
mate was that being fully adherent to statins reduced the
hazard of cardiovascular mortality by about 47 % (HR:
0.53; 95 % CI: 0.46 to 0.61) (Table 3). This estimate was
similar to the population-averaged estimate; using the
parametric G-formula, in the scenario where all patients
were fully adherent, the hazard was reduced by 49 % (HR:
0.51; 95 % CI 0.43 to 0.61). Including birth cohort in the
G-formula did not change this population-averaged
estimate substantially (HR: 0.50, 95 % CI 0.42 to 0.59).
Table 1 Percentage of users in the sample with at least one
dispensing for each drug
Drug type ATC-code % of patients with at
least one dispensing
Antithrombotics B01 61 %
Renin-angiotensin C09 63 %
Beta blockers C07 60 %
Diuretics C03 56 %
Antidiabetics A10 33 %
Anti-inflammatory M01 34 %
Calcium channel blockers C08 31 %
Cardiac therapy C01 20 %
Obstructive airway R03 19 %
Antihypertensives a C02 2 %
athe category ‘Diuretics’ includes important drugs used for
antihypertensive properties
Table 2 Percentage of patients that switched cardiovascular
drug therapy
Drugs switched % of patients
that switched
Simvastatin (C10AA01) to Atorvastatin (C10AA05) 12.0 %
Atorvastatin (C10AA05) to Simvastatin (C10AA01) 9.0 %
Gemfibrozil (C10AB04) to Simvastatin (C10AA01) 6.8 %
Simvastatin (C10AA01) to Gemfibrozil (C10AB04) 6.8 %
Simvastatin (C10AA01) to Rosuvastatin (C10AA07) 5.8 %
Gemfibrozil (C10AB04) to Atorvastatin (C10AA05) 5.6 %
Atorvastatin (C10AA05) to Gemfibrozil (C10AB04) 5.6 %
Other combinations <5.0 % each
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Falsification end-points
Being adherent to statin therapy was not protective
against respiratory, endocrine, nutritional and metabolic
disease in the small model (HR: 0.93, 95 % CI: 0.79 to
1.09), which argues against the presence healthy adherer
bias (Table 3). However, in the large model it did appear
to be protective (HR: 0.68, 95 % CI: 0.58 to 0.80). Separ-
ate analyses for mortality due to respiratory diseases,
and mortality due to endocrine, nutritional and meta-
bolic diseases yielded results of similar magnitude.
Subset analyses
The estimated effect of adherence to statin therapy on
the hazard of cardiovascular mortality changed over time
(Table 3). The difference between the estimates of the
large and the small models, as an indication of measured
confounding, was larger in more recent years.
Discussion
For the population aged 46 to 100 years in the study
period 1996 to 2012 in the Netherlands, both the condi-
tional effect estimate and the population averaged effect
estimate indicated that being adherent to statin therapy
was strongly protective against cardiovascular mortality.
Including birth cohort or neighborhood SES covariates
did not affect the estimate of the effect of the primary
exposure on the primary outcome. The differences be-
tween the estimates from the small and the large Cox
models substantially changed between time periods.
Furthermore, in the simple model, the falsification end-
point did not indicate bias, but in the large model there
was a strong indication of bias. Confounding also
appeared to differ by calendar period.
Falsification end-points and sources of bias
In this study, we avoided confounding by indication by
comparing statin therapy starters amongst each other.
We investigated whether healthy adherer bias affected
our results by also analyzing the effect of statin adher-
ence on falsification outcomes. In the small model, statin
adherence was not protective against falsification out-
comes, which means there is no indication of healthy
adherer bias. However, in the large model, statin adher-
ence did become protective against the falsification
outcomes, while also becoming protective against car-
diovascular mortality. A criticism of the falsification
end-point approach is that the falsification end-point
and the primary end-point are not necessarily affected
by the same bias [9]. However, the effect of statin adher-
ence on both outcomes became biased in the same dir-
ection, and the relative magnitude of the bias was also
the same (0.70/0.53 = 1.32 for CVD and 0.93/0.68 = 1.36
for the falsification outcomes). These indicate that both
outcomes were likely affected by the same bias.
Some causal pathways from statin utilization to re-
spiratory, endocrine and metabolic mortality are pos-
sible. We believe these pathways to be limited, and
therefore to only have a minor effect on the association
Fig. 1 Adherence over time among individuals aged 46 to 100 in the period 1996 to 2012
Table 3 Effect estimates of adherence to statin therapy on cardiovascular mortality by calendar period
Calendar years Small model Large model Difference
in HR
# events
HR 95 % CI HR 95 % CI
1994–2002 0.85 0.55 to 1.34 0.79 0.44 to 1.40 0.06 158
2003–2006 0.58 0.45 to 0.76 0.46 0.35 to 0.59 0.12 642
2007–2012 0.77 0.65 to 0.92 0.54 0.45 to 0.65 0.23 765
Overall (1994–2002) 0.70 0.61 to 0.81 0.53 0.46 to 0.61 0.17 1565
Falsification outcome (1994–2002) 0.93 0.97 to 1.09 0.68 0.58 to 0.80 0.25 1179
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between statin utilization and the falsification outcomes.
Nevertheless, ideally, we would have chosen deaths due
to external causes (e.g. deaths as a result of accidents
and physical abuse) as falsification end-points, as they
are even less likely to be affected by lipid levels than the
current choice. However, only ~100 events due to this
cause were recorded, and hence this choice is
underpowered.
Since healthy adherer bias appears to be limited, and
the bias is caused by adjusting for an increased set of co-
variates, the source of the bias is likely either overadjust-
ment or competing risks [25, 26]. Overadjustment bias
can be caused by conditioning on mediators or on col-
liders [25]. However, none of the added variables should
mediate the effect of statin adherence on cardiovascular
mortality (or the falsification end-points), and none
should function as colliders in this context. The bias is
therefore likely caused by competing risks. Next to car-
diovascular mortality (and the falsification outcomes),
patients may die from a large number of other causes of
death. By fitting a Cox model to data in which compet-
ing risks are present, we model the cause-specific haz-
ard. Cause specific hazards are the hazards at time t of a
specific cause of death conditional on surviving to time
t. That is, conditional on not having died from the event
under study before time t, as well as not having died
from a competing event before time t. Therefore, the
hazards of the competing cause of death affect the haz-
ard of cardiovascular mortality. If the additional covari-
ates in the large Cox model in this study affect the
hazards of competing risks, then this also affects the
hazard of cardiovascular mortality and the falsification
end-points. This problem would not arise if we could
model the marginal cause-specific hazard, i.e. the hazard
of cardiovascular mortality where the hazards of com-
peting causes are 0. However, the marginal cause-
specific hazards are unfortunately unobservable.
We also compared bias between different calendar
periods, and observed that the difference between the ef-
fect estimates of the small and the large models in-
creased over calendar time. Overall, in the large model,
the effect estimates of statin adherence on cardiovascu-
lar mortality were closer to that of clinical trials in the
period prior to 2002. In the period prior to the year
2002, statins were especially indicated for patients be-
tween ages 50 to 70 years with hypercholesterolemia [1].
Around the year 2002, important studies showed that
also patients above age 70, and that diabetic patients,
benefitted from statins. In the Netherlands in the year
2006, the age restrictions were formally abolished.
Therefore, the patient population likely resembled the
trial population more closely shortly after the introduc-
tion of statins in the population, and hence effect esti-
mates are also more similar. Furthermore, it is possible
that due to the studies and guideline changes, the pa-
tient population became more heterogeneous over time,
and adjustment for potential confounders more strongly
changed the effect estimate of statin therapy.
Parametric G-formula
Because Cox models are non-collapsible [22], we
used the parametric G-formula (a method of direct
standardization) to produce a population averaged
effect estimate for the effect of statin therapy on the
hazard of cardiovascular mortality. The parametric G-
formula is only rarely employed [24], but can be highly
useful, as it shows the effect of a time-dependent inter-
vention on the population level. In our study, the
population-averaged estimate shows the effect on the
hazard if all statin users in the population were fully
adherent at all times from first dispensing onwards,
compared to the situation where they were all fully
non-adherent at all times. The population averaged es-
timate is close to the conditional effect estimate, which
is likely caused by the low hazard of cardiovascular
mortality (at any time point) in our sample. For this
reason, we chose not to apply the parametric G-
formula in subset analyses.
Birth cohort and confounding & effect modification
In this study, we conclude that non-linear birth cohort
does not confound the estimates of the effect of statin
adherence on the hazard of cardiovascular mortality. It
may still be possible that the linear part of birth cohort
confounds the outcome, however this is less problematic
because age and calendar time are commonly included
in analyses of drug effectiveness, and would therefore
also include linear birth cohort through the dependency
between the three variables [21]. In this way, it may even
be possible to model away a true birth cohort effect by
using non-linear terms (including interaction effects) for
age and period.
If birth cohort is (conditional on age and calendar
year) related to health behavior, then this would be re-
levant for two reasons. First, birth cohort may affect
healthy adherer bias and therefore controlling for birth
cohort should result in more valid estimates of the
causal effect of statin adherence on cardiovascular mor-
tality when information on health behavior itself is un-
available. However, since we did not find evidence for
confounding by birth cohort, it is less likely that birth
cohort is strongly related to health behavior on the pa-
tient level. Secondly, it may mean that the effectiveness
of drugs is different for different birth cohorts, because
cohorts would have differences in the way they utilize
drugs. Since we did not find evidence for effect modifi-
cation by birth cohort, this also appears to be less likely.
It could be argued that since adherence to statins and
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other drugs is itself an indicator of health behavior, look-
ing at statin adherence (and adherence of other drugs)
removes the effect of birth cohort on cardiovascular
mortality.
Statin therapy effectiveness
Being adherent to statins appears to be protective
against cardiovascular mortality, which is in line with
the literature, though clinical effect may differ between
subgroups (e.g. [27-29]). We shall here interpret the re-
sults from the small Cox model, as the larger model is
known to be biased. In the small model, the population-
averaged hazard ratio of statin adherence was estimated
to be 0.70 (95 % CI: 0.61 to 0.81). This means that the
hazard of cardiovascular mortality of a patient who is
fully adherent is 30 % lower than the hazard of cardio-
vascular mortality in a similar patient who is completely
non-adherent. This estimate is close to that of a
Cochrane review of randomized clinical trials, but the
confidence intervals do not overlap. In the Cochrane re-
view, the hazard was estimated to be reduced by 17 %
against fatal cardiovascular events (RR: 0.83, 95 % CI:
0.72 to 0.96). Differences may be caused by our study
population being a relatively low-risk population for
cardiovascular mortality (1565/49,688 * 100 % ≈ 3 %
probability of CVD death).
Evaluation of data and methods
The findings of the study in regard to statin effectiveness
are not directly comparable with those of earlier obser-
vational studies because the outcome definitions dif-
fered, as well as the definition of the primary exposure.
To the best of our knowledge, this is the first study that
used time-varying adherence to statin therapy as the pri-
mary exposure. Other studies that have related statin ad-
herence to cardiovascular outcomes commonly calculate
adherence over a fixed period, such as adherence in the
first year. Using adherence in the first year is useful for
predictive (and therefore clinical) purposes. However,
time invariant adherence will likely be less strongly re-
lated to the outcome; a patient’s adherence in the first
year should not be strongly related to his or her adher-
ence in the 5th year of follow up, and therefore to the
hazard of mortality in the fifth or sixth year. This shows
the usefulness of accounting for time-varying drug ad-
herence [12].
The proportion of days covered method is a method
of indirect observation. It’s strength, compared to direct
methods, is that direct methods are intensive and inva-
sive, which therefore often severely limit the number of
observations that can be performed [12]. However, a
limitation of indirect methods is that it cannot be
observed if patients take their statin [12]. This over-
estimates adherence and thereby biases statin effect
estimates towards the null. However, this bias may be
limited with the proportion of days covered method,
given that patients who forget to take their statin are less
quickly in need of new statins and therefore their adher-
ence estimate is adjusted downwards.
More than 90 % of the patients that were censored in
the study were subject to administrative censoring,
which is non-informative. That is, they were still being
followed when the study ended on the 31st of December
2012. The remaining number of patients were censored
during the study: if this did not occur due to competing
mortality, it could only occur due to patients moving
out of the IADB coverage area due to the type of data
sources that were used. It is unknown to what extent a
move is related to impending cardiovascular mortality.
Due to data limitations, we were unable to determine
the underlying health conditions of individual patients
(except by using drugs dispensed as proxies for these
conditions). Therefore, we could not determine which
patients had familial hypercholesterolemia. However, the
prevalence of this illness in the Netherlands is ~0.25 %,
and therefore is unlikely to have strongly biased our
estimates [30].
Conclusions
In time-to-event analysis in a competing risks setting,
adjusting for confounding, while necessary, can cause
new biases to emerge. Falsification end-points can help
detect this bias, and is therefore a useful approach in
such a complex setting. However, this study generates
evidence that for the population aged 46 to 100 in the
study period 1996 to 2012 in the Netherlands, being
adherent to statin therapy appeared to lower the risk
of cardiovascular mortality, compared to being not
adherent.
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